Sentence: We conducted a dose-escalating study of daunorubicin combined to fixed doses of IM ( imatinib mesylate , 600 mg/d ) and cytarabine ( 200 mg/d for 7 days ) , followed by hematopoietic stem cell transplantation or maintenance therapy with single-agent IM in patients with MBC-CML at onset or after failure of therapy excluding TKIs .
Drug combination annotation:
[{'class': 'POS', 'spans': ['daunorubicin', 'imatinib', 'cytarabine'], 'is_context_needed': True}]